Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.52 |
| ▸ | CCR5 | P51681 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904275 | 1.00 | EPHX2 (0.52) | EPHX2CCR5CYP2D6KCNH2CYP2C9 | |
| SCHEMBL6011425 | 0.83 | CCR2 (0.49) | EPHX2CCR5PTGS2ESR2 | |
| SCHEMBL4976401 | 0.83 | CCR2 (0.49) | EPHX2CCR5PTGS2ESR2 | |
| SCHEMBL4443843 | 0.82 | EPHX2 (0.49) | EPHX2CCR5CYP2D6KCNH2CYP2C9 | |
| SCHEMBL4915630 | 0.82 | EPHX2 (0.43) | EPHX2CCR5CYP2D6KCNH2CYP2C9 | |
| SCHEMBL4915625 | 0.82 | EPHX2 (0.43) | EPHX2CCR5CYP2D6KCNH2CYP2C9 | |
| SCHEMBL6011782 | 0.81 | EPHX2 (0.48) | EPHX2CCR5CYP2D6KCNH2CYP2C9 | |
| SCHEMBL5494676 | 0.77 | CCR5 (0.46) | EPHX2CCR5PTGS2ESR2 | |
| SCHEMBL5490989 | 0.77 | CCR5 (0.46) | EPHX2CCR5PTGS2ESR2 | |
| SCHEMBL5235475 | 0.77 | CCR5 (0.43) | EPHX2CCR5CYP2D6KCNH2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| EP-1648871-A1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005007629-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | CCR5, CCR2, CCR7 | EPHX2 2194/4885CCR5 1/4885CYP2D6 1882/4885 |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | EPHX2 1726/4885CCR5 1/4885CYP2D6 690/4885 |
| US-20080200460-A1 | Chemical Compounds | CCR5, CXCR4, CXCR5 | EPHX2 523/4885CCR5 1/4885CYP2D6 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.